Abstract: The present invention relates to an aqueous solution comprising burlulipase which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceuticals. Such pharmaceuticals are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceuticals are particularly suitable for treating patients having cystic fibrosis and in pediatrics. Another aspect of the present invention relates to container-packaged solutions and pharmaceuticals as mentioned above, which are containers produced by the blow-fill-seal method, and to methods for producing such packaged solutions and pharmaceuticals.
Type:
Application
Filed:
July 19, 2022
Publication date:
January 19, 2023
Applicant:
NORDMARK PHARMA GMBH
Inventors:
Richard Fuhrherr, Annika Müller-Lucks, Katharina Rützel, Jan Lüdemann, Martin Werner
Abstract: The present invention relates to an orodispersible tablet characterized in that it includes burlulipase. It also relates to liquid pharmaceutical compositions that contain solutions of such orodispersible tablets in water or other beverages. It relates to drugs that contain or consist of such orodispersible tablets or solutions. In particular, it relates to such drugs that are suitable for treating digestive problems, in particular exocrine pancreatic insufficiency used to treat digestive problems. In particular, they are for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients and for treatment of exocrine pancreatic insufficiency in pediatric patients.
Type:
Grant
Filed:
March 5, 2018
Date of Patent:
October 11, 2022
Assignee:
Nordmark Pharma GmbH
Inventors:
Richard Fuhrherr, Jan Lüdemann, Lisa Garrett
Abstract: The present invention relates to an aqueous solution comprising burlulipase which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceuticals. Such pharmaceuticals are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceuticals are particularly suitable for treating patients having cystic fibrosis and in pediatrics. Another aspect of the present invention relates to container-packaged solutions and pharmaceuticals as mentioned above, which are containers produced by the blow-fill-seal method, and to methods for producing such packaged solutions and pharmaceuticals.
Type:
Grant
Filed:
March 5, 2018
Date of Patent:
September 13, 2022
Assignee:
NORDMARK PHARMA GMBH
Inventors:
Richard Fuhrherr, Annika Müller-Lucks, Katharina Rützel, Jan Lüdemann, Martin Werner
Abstract: The present invention relates to a method for purifying at least one enzyme selected from the group consisting of collagenase type I, collagenase type II, neutral protease and clostripain from a mixture of substances, comprising as a method step at least one hydrophobic interaction chromatography, characterized in that, in the hydrophobic interaction chromatography, the stationary phase comprises a material selected from the group consisting of polypropylene glycol and butyl sepharose. The present invention further relates to the use of an enzyme thus purified for pharmaceutical, cosmetic and/or biochemical purposes.
Type:
Application
Filed:
February 14, 2019
Publication date:
May 5, 2022
Applicant:
NORDMARK PHARMA GMBH
Inventors:
THOMAS SCHRÄDER, JÖRG LAMBRECHT, STEFAN DÖDING